A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) (Q90693178)
Jump to navigation
Jump to search
clinical trial
- A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) |
clinical trial |
|
Statements
CTII-nCoV (English)
0 references
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years (English)
0 references
12 April 2020
0 references
31 January 2021
0 references
508
0 references
18 year
0 references